Athebio Enters Collaboration Agreement with 3T Biosciences

September 15, 2022, Switzerland, Schlieren-Zurich

Athebio AG, an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), today announced that it has entered into a collaboration agreement with 3T Biosciences (“3T”), an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response guided target discovery approach.

Under the agreement, Athebio will provide 3T with Athebody® DARPins selected from its proprietary library against undisclosed peptide antigens presented on the cell surface by major histocompatibility complex (MHC) proteins. 3T may option the selected Athebody® DARPins for further development.

“We are looking forward to working with the highly talented team at 3T Biosciences. We believe that Athebody® DARPins have ideal properties to optimally recognize pMHC targets with very high specificity, which is crucial to be successful in this space,” said Patrik Forrer, CEO and Chairman at Athebio, and one of the inventors of the DARPin technology.

“Combined with other key characteristics like their superior manufacturability and their ease of constructing multi-specific binders, Athebody® DARPins will prove a great asset for various molecular formats, including the field of T-cell engagement. We are looking forward to exploring this huge potential together with 3T Biosciences.”

About Athebio

Athebio enables its partners to develop next-generation therapeutics based on leading-edge designed ankyrin repeat protein (DARPin) technology. Rather than building up its own pipeline, Athebio generates tailor-made Athebody® DARPins for its partners. Athebio has brought the DARPin technology to the next level through the development of its proprietary Athebody® DARPin Platform. Athebody® DARPins offer game-changing advantages for generating targeted therapeutics, including high stability, small size, reliable folding, excellent target affinity and specificity, species cross-reactivity, ease of generating multi-specificity, superb developability, and good freedom-to-operate prospects. Athebio enables its partners to rapidly expand their biologics pipelines by providing Athebody® DARPins to unlock therapeutic options not easily accessible with current antibody technologies.

For additional information please contact:
Athebio AG
+41 44 508 08 28
contact@athebio.com
https://www.athebio.com